Memorandum of Understanding between AFFINOMICS, NIH and Human Protein Atlas
In September 2013, the AFFINOMICS consortium signed a Memorandum of Understanding (MOU) with the NIH Protein Capture Reagents Program, and the Human Protein Atlas. The purpose of the MOU is to set up cooperative activities in the production and use of protein affinity reagents. The three programmes have unique missions but many common goals. The cooperation guided by this MOU should benefit all programmes and the main goal of generating valuable resources for protein affinity reagents for the scientific community.
NCI and AFFINOMICS Coordinate Affinity Reagent Production and Characterisation
As of February 2012, the AFFINOMICS Consortium and the US National Cancer Institute (NCI, part of the National Institutes of Health) formally signed a memorandum of understanding to coordinate activities and avoid duplications in the production of cancer-associated protein targets, binders against those, binder characterisation, and the subsequent public dissemination of products and data to the global research community.
The NCI’s Antibody Characterization Program (a component in NCI’s Cancer Clinical Proteomics Research), provides monoclonal antibodies to human cancer-associated proteins. Characterisation may include western blot, surface plasmon resonance, indirect ELISA, immunohistochemistry, and immuno-mass spectroscopy. All antigens and antibodies are expressed, purified, produced and characterised using standard operating procedures which are freely accessible to the public. The antibodies and all characterisation data are then made publicly available. The NCI antibody data portal provides information and access for a large number of reagents that are needed for effective proteomic analysis.
Further reading on international reagent generation programmes